Literature DB >> 33224826

Comparison between surgery plus radiotherapy and radiotherapy alone in treating breast cancer patients with ipsilateral supraclavicular lymph node metastasis.

Xian-Fu Sun1, Ying-Jie Wang2, Tao Huang1, Lian-Jie Niu1, Qiang Zhang1, Zhen-Zhen Liu1.   

Abstract

BACKGROUND: Ipsilateral supraclavicular lymph node metastasis (ISLM) with breast cancer patients has always been a hard problem for breast surgery. It is generally believed that radiotherapy can benefit the survival of patients, but whether local surgical resection is needed or not is controversial. The study aims to compare the efficacy between supraclavicular lymph node (SLN) dissection combined with radiotherapy and radiotherapy alone in the treatment of breast cancer with ISLM.
METHODS: A retrospective analysis was performed using 122 cases of breast cancer with ISLM but without distant metastasis. Among them, 14 cases were eliminated due to insufficient data. The 108 remaining cases were divided into 2 groups based on different treatment proposals for metastatic SLNs. The groups were dissection plus radiotherapy (surgery group), and simple radiotherapy (radiotherapy group).
RESULTS: For the 108 patients, the overall 5-year disease-free survival (DFS) and overall survival (OS) rates were 30.6% and 67.8%, respectively. In the surgery group, distant metastases occurred in 41 patients, and the 5-year DFS was 34.3%; in the radiotherapy group, 18 patients had distant metastases, and the 5-year DFS was 26.1%; the difference was not statistically significant (P>0.05). In the surgery group, 11 patients died, and the 5-year OS rate was 67.9%; in the radiotherapy group, 6 patients died, and the 5-year OS rate was 67.5%; the difference was not statistically significant (P>0.05).
CONCLUSIONS: The dissection of SLN combined with radiotherapy and radiotherapy alone had similar effects on the survival rates in breast cancer patients with ISLM. The local control in the surgery group was better than that in the radiotherapy group. The status of estrogen receptors (ER) and the number of axillary lymph node metastases were independent influencing factors of DFS. The ER status is an independent factor affecting the OS rate of patients. 2020 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Breast cancer; estrogen receptor; radiotherapy; regional surgery; supraclavicular lymph node metastasis (ISLM)

Year:  2020        PMID: 33224826      PMCID: PMC7667124          DOI: 10.21037/gs-20-691

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  24 in total

Review 1.  Supraclavicular metastases from distant primaries: what is the role of the head and neck surgeon?

Authors:  Tom Aldridge; Atul Kusanale; Serryth Colbert; Peter A Brennan
Journal:  Br J Oral Maxillofac Surg       Date:  2012-05-14       Impact factor: 1.651

2.  Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.

Authors:  R A Brito; V Valero; A U Buzdar; D J Booser; F Ames; E Strom; M Ross; R L Theriault; D Frye; S W Kau; L Asmar; M McNeese; S E Singletary; G N Hortobagyi
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

3.  A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome.

Authors:  R L Camp; E B Rimm; D L Rimm
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

Review 4.  Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why?

Authors:  Luca Bertero; Federica Massa; Jasna Metovic; Roberto Zanetti; Isabella Castellano; Umberto Ricardi; Mauro Papotti; Paola Cassoni
Journal:  Virchows Arch       Date:  2017-12-05       Impact factor: 4.064

5.  [A case of breast cancer with postoperative metastasis to the supraclavicular lymph nodes-recurrence-free survival achieved by surgical excision following chemotherapy].

Authors:  Kenji Tezuka; Nobuhiro Dan; Masashige Tendo; Takeshi Hori; Hiroji Nishino
Journal:  Gan To Kagaku Ryoho       Date:  2011-08

6.  Incidence and time of occurrence of regional recurrence in stage I-II breast cancer: value of adjuvant irradiation.

Authors:  J Fodor; J Toth; T Major; C Polgar; G Nemeth
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-05-01       Impact factor: 7.038

7.  Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study.

Authors:  M Perloff; G J Lesnick; A Korzun; F Chu; J F Holland; M P Thirlwell; R R Ellison; R W Carey; L Leone; V Weinberg
Journal:  J Clin Oncol       Date:  1988-02       Impact factor: 44.544

Review 8.  Evaluating the current evidence to support therapeutic mammoplasty or breast-conserving surgery as an alternative to mastectomy in the treatment of multifocal and multicentric breast cancers.

Authors:  Zoe Ellen Winters; Lorenzo Bernaudo
Journal:  Gland Surg       Date:  2018-12

9.  Long-term outcomes of immediate autologous breast reconstruction after definite adjuvant therapy in intermediate and locally advanced breast cancer.

Authors:  Won Sup Yoon; Chai Hong Rim; Dae Sik Yang; Jung Ae Lee; Gil Soo Son; Young Woo Chang; Sang Uk Woo; Deok-Woo Kim; Eun-Sang Dhong
Journal:  Ann Transl Med       Date:  2019-12

10.  Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Authors:  Maggie C U Cheang; Stephen K Chia; David Voduc; Dongxia Gao; Samuel Leung; Jacqueline Snider; Mark Watson; Sherri Davies; Philip S Bernard; Joel S Parker; Charles M Perou; Matthew J Ellis; Torsten O Nielsen
Journal:  J Natl Cancer Inst       Date:  2009-05-12       Impact factor: 13.506

View more
  1 in total

1.  Long-Term Outcomes of Breast Cancer Patients Who Underwent Selective Neck Dissection for Metachronous Isolated Supraclavicular Nodal Metastasis.

Authors:  Shin-Cheh Chen; Shih-Che Shen; Chi-Chang Yu; Ting-Shuo Huang; Yung-Feng Lo; Hsien-Kun Chang; Yung-Chang Lin; Wen-Ling Kuo; Hsiu-Pei Tsai; Hsu-Huan Chou; Li-Yu Lee; Yi-Ting Huang
Journal:  Cancers (Basel)       Date:  2021-12-29       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.